Abstract Details

Title Piedmont Brain Tumor Center’s Experience with GammaTile Intracranial Brachytherapy for Malignant Intracranial Tumors

Topic Neuro-oncology

Presentation(s) P6 - Poster Session 6 (5:30 PM-6:30 PM)

Poster/Presentation
Number 4-006

Objective Describe the real-world experience a high-volume community-based referral hospital in metropolitan Atlanta with Surgically Targeted Radiation Therapy (START) which involves implanting Cesium-131 seeds into the tumor cavity following resection of new and recurrent malignant intracranial tumors.

Background Standard of care for malignant intracranial tumors involves maximal safe surgical resection, followed by external beam radiation (EBRT) +/- chemotherapy. However, standard post-operative EBRT has been limited by uneven dose distribution, complicated workflow, extended procedural times, equipment costs, frequent adverse events (AEs), and time-delays limiting adjunctive therapies.

Design/Methods Between January 2020 and September 2021, a total of 17 patients, with a total of 19 lesions, were treated. A craniotomy for maximal safe resection was performed for each lesion with near or gross-total resection followed by implantation with cesium-131 GammaTile brachytherapy. Clinical and patient-reported outcomes are collected, including demographics, pathology, AEs, quality of life, feasibility, economics, length-of-stay, local control (LC) and/or distant recurrence, overall survival (OS).

Results By submission, we've treated 8 patients with brain metastases (BM) with 10 total lesions, 7 with recurrent glioblastoma (GBM), and 2 with recurrent malignant meningiomas (MM). For each group, LC and OS were as follows: BM was 10.2 months and 12 months; GBM was 5.6 months and 7 months; MM was 6 months and 7.5 months, respectively. One case of radiation necrosis was noted in the MM group at 5.6 months following a heavily pre-treated patient with previous EBRT. No other surgical complications were noted. To-date, it appears feasible and similar peri-op/post-op neurologic events, length-of-stay, as compared to historical controls.

Conclusions GammaTile brachytherapy facilitates two therapies at the time of resection for new and recurrent intracranial neoplasms. Our to-date real-world experience supports it being a safe, feasible, and effective therapy for surgical candidates. Our evolving results aim to contribute to future trial design and optimal sequencing of GammaTile.

Authors/Disclosures
Erin M. Dunbar, MD (Piedmont Physicians Neuro-Oncology) PRESENTER	Dr. Dunbar has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��